Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Desensitization to Peanut in Peanut-Allergic Subjects (ARC002 Extension of ARC001)
2021-002533-42Phase 2
- Sponsor
- Aimmune Therapeutics, Inc.
- Start
- Dec 2021
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of peanut protein in peanut allergy, sponsored by Aimmune Therapeutics, Inc. Primary endpoint: Incidence of treatment-related adverse events.
02
Drugs
peanut protein
03
Conditions
peanut allergy
Beyond the preview
Go deeper on 2021-002533-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002533-42.